Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET

Company Participants

Meredith Kaya - SVP of IR & Strategic Finance
Cedric Francois - Co-Founder & CEO
Adam Townsend - COO
Caroline Baumal - Chief Medical Officer
Tim Sullivan - CFO

Conference Call Participants

Jonathan Miller - Evercore
Anupam Rama - J.P. Morgan
Yigal Nochomovitz - Citigroup
Steven Seedhouse - Raymond James
Colleen Kusy - Baird
Phil Nadeau - TD Cowen
Ivy Wang - Jefferies
Eliana Merle - UBS
Annabel Samimy - Stifel
Francois Brisebois - Oppenheimer
Douglas Tsao - H.C. Wainwright
Biren Amin - Piper Sandler
Graig Suvannavejh - Mizuho

Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised, today's call is being recorded.

I would now like to hand the conference over to Meredith Kaya, Senior Vice President, Investor Relations and Strategic Finance. Please go ahead.

Meredith Kaya

Good morning, and thank you for joining us to discuss Apellis second quarter 2024 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Operating Officer, Adam Townsend; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.

Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.

Now, I'll turn the call over to Cedric.

Cedric Francois

Thank you, Meredith. And thank you all for joining us this morning. We are in a unique position today with one and the potential for two, blockbuster drugs in the market, SYFOVRE and EMPAVELI, both of which are making a meaningful difference for patients.

Past six months have been a period of continued progress and execution by the Apellis team, but we recognize that there are questions around the competitive landscape for SYFOVRE. Given this, I wanted to share some of my thoughts. SYFOVRE is the market leader in a category with only two available drugs, 1.5 million highly motivated patients and a long runway for continued growth.